Characterization of the human FcγRIIB gene promoter: human zinc-finger proteins (ZNF140 and ZNF91) that bind to different regions as transcription repressors

Tadahiro Nishimura, Tadashi Narita, Emi Miyazaki, Tohru Ito, Norihiro Nishimoto1, Kazuyuki Yoshizaki1, Joseph A. Martial2, Eric J. Bellfroid2, Henrik Vissing3 and Tadayoshi Taniyama

Laboratory of Immunoregulation, Department of Immunology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
1Department of Immunology, School of Health and Sport Science, Osaka University, Suita 565-0871, Japan
2Laboratory of Molecular Biology and Genetics, University of Liege, Institute of Chemistry B6, B-4000 Sart-Tilman, Belgium
3Molecular and Cellular Biology, Novo Nordisk, DK-2880, Bagsvaerd, Denmark

Keywords: Fcγ receptor II, repressor, transcription, zinc-finger protein

Abstract

Expression of the human low-affinity Fc receptors for IgG (human FcγRII) is differentially regulated. We report here the characterization of the promoter structure of the human FcγRIIB gene and the isolation of the promoter region-binding proteins by a yeast one-hybrid assay. The minimal 154-bp region upstream from the transcription start site of the human FcγRIIB gene was shown to possess promoter activity in a variety of cells. An electrophoretic mobility shift assay indicated that multiple nuclear factors in cell extracts bind to the two regions [F2-3 (–110 to –93) and F4-3 (–47 to –31)] of the human FcγRIIB gene promoter. Mutation analysis indicated that GGGAGGAGC (–105 to –97) and AATTTGTTTGCC (–47 to –36) sequences are responsible for binding to nuclear factors respectively. By using GGGAGGAGC and AATTTGTTTGCC as bait sequences, we cloned two zinc-finger proteins (ZNF140 and ZNF91) that bind to the F2-3 and F4-3 regions within the promoter of the human FcγRIIB gene respectively. When the ZNF140 and ZNF91 were transfected with reporter plasmid, both showed repressor activity with additive effects. Thus, these results indicate that these cloned ZNF140 and ZNF91 proteins function as repressors for the human FcγRIIB transcription.

Introduction

In humans, there are three classes of Fc receptor for IgG, i.e. FcγRI, FcγRII and FcγRIII (1–3), and these have been shown to be involved in phagocytosis (4), clearance of immune complexes (5), antibody-dependent cellular cytotoxicity (6,7), release of inflammatory mediators (8), regulation of Ig synthesis (9) and superoxide production (10). FcγRI and FcγRIII are expressed in macrophages, and in natural killer cells, neutrophils, macrophages and a subset of T cells respectively. On the other hand, FcγRII is found in various types of cells, including macrophages, neutrophils, platelets, B cells and epithelial cells.

Three human FcγRII genes (FcγRIIA, FcγRIIB and FcγRIIC) that contain eight exons and seven introns were previously cloned (11,12). Alternative splicing of at least two (FcγRIIA and FcγRIIB) of these three genes has been shown to result in the production of multiple transcripts (13). These transcripts are FcγRIIA1, FcγRIIA2, FcγRIIB1, FcγRIIB2 and FcγRIIB3. Myelomonocytic cells contain all three FcγRII transcripts, predominantly the FcγRIIA1 transcript, the FcγRIIB1 and FcγRIIB2 transcripts, and the FcγRIIC transcript. B cells do not express FcγRIIA, but contain both the FcγRIIB1 and FcγRIIB2 transcripts and the FcγRIIC transcript. Megakary-
ocytic cells contain predominantly FcγRIIA transcripts. Further, human epithelial cells and trophoblasts also express all three FcγRII transcripts, predominantly the FcγRIIC transcript (14, 15). Thus, these findings indicate that different regulatory mechanisms exist among these three FcγRII gene expressions in a variety of cell types.

McKenzie and his group (16) characterized the 5' region of the human FcγRIIA gene. They reported that the FcγRIIA gene, which consists of nine exons, has two discrete transcription start sites. One start site was mapped to a 5'-untranslated (5'-UT) exon ~1 kb 5' to the ATG translation initiation codon and the second start site was mapped near the ATG codon. However, these authors did not report the precise functional characterization of the human FcγRIIA promoter and the molecular mechanism underlying the regulation of the human FcγRII gene expression is still obscure.

To unravel the molecular mechanism of the regulation of the human FcγRII gene transcription, we isolated the human FcγRIIB gene promoter and identified two different region-binding proteins (F2-3 and F4-3 binding proteins) within the promoter region of the human FcγRIIB gene by electrophoretic mobility shift assay (EMSA). We also cloned two different zinc-finger proteins (ZNF140 and ZNF91) that can bind to the F2-3 and F4-3 regions within the human FcγRIIB promoter respectively. These human zinc-finger proteins (ZNF140 and ZNF91) function as repressors for the human FcγRIIB transcription. When they were simultaneously expressed, the two proteins demonstrated an additive suppressive effect.

Methods

Plasmids and phage library

The EMBL3 genomic phage library (kindly provided by the Japanese Cancer Research Resources Bank, Tokyo, Japan) was used for the screening of human FcγRIIB genomic genes. The pSVOCAT was obtained from Wako Pure Chemical Industries (Osaka, Japan). The pBluescript II KS+ (pBSIIKS+), and pCAT-enhancer (pCAT-EN), pGL3-Enhancer (pGL3EN) and pSV-β-galactosidase control vector (pSVβgal) were purchased from Stratagene (La Jolla, CA) and Promega (Madison, WI), respectively. The pCAGGS was kindly supplied by Dr Miyazaki (17) and pcDNA3.1/Hygro(+) (pcDNA3.1) was obtained from Invitrogen (Carlsbad, CA).

Cloning of the human FcγRIIB gene promoter region

Four clones were isolated from the EMBL3 phase library using the 32P-labeled 700-bp PstI fragment of the PC23 cDNA as a probe (18) under high-stringent conditions. Construction of deletion mutants using pBSIIKS+ plasmid was performed using exonuclease III (Stratagene) according to the manufacturer's instructions.

Construction of plasmids

The 1.5-kb EcoR1–NarI fragment of the cloned human FcγRIIB gene was filled in and ligated to SalI linker, and then ligated to the SalI site of pSVOCAT to give pFCR5CAT. The same 1.5-kb fragment was inserted into the SalI sites of pCAT-EN to yield pFCR5CAT-EN. The various deletion mutants were prepared using exonuclease III and sequenced, and the resulting inserts were ligated into the SalI site of pCAT-EN.

Nuclear extracts and EMSA

Nuclear extracts were prepared by the method of Dignam et al. (21). EMSA was performed as follows. A fragment (~154 to +21 bp region) and oligonucleotides were end-labeled using [32P]dCTP and Klenow fragment. Nuclear extracts (20 µg) were incubated at 16°C for 20 min with 32P-labeled fragment (~1 ng, 25,000 c.p.m./ng) in 20 µl of binding buffer containing 40 mM Tris–HCl (pH 7.5), 200 mM NaCl, 2 mM DTT, 10% Glycerol, 0.05% NP-40, 5 mM MgCl2, 50 µg/ml poly(dG–dC):poly(dG–dC) (Amersham Pharmacia Biotech, Little Chalfont, UK) and 1 mM EDTA. In our competition studies, a 150 M excess of unlabeled oligonucleotide competitors was added. The DNA–protein complexes were separated in a 4% polyacrylamide gel using a running buffer containing 50 mM Tris–HCl (pH 7.8), 380 mM lysine and 1 mM EDTA.

Yeast one-hybrid assay

The Matchmaker one-hybrid system from Clontech (Palo Alto, CA) was used according to the manufacturer's instructions. Briefly, the double-stranded oligonucleotides with the 5'-(AAAGGGAGGAGC)×4–3' (for F2-3-binding protein) and 5'-(AATTTGTTTGCC)×3-3' (for F4-3-binding protein) fragments were subcloned into the pHISI-1 and pLacZi. These plasmids (F2-3-EL/pHISI-1 and F2-3-EL/pLacZi for the F2-3-binding protein and F4-3-EL/pHISI-1 and F4-3-EL/pLacZi for the F4-3-binding protein) were successively introduced into yeast YM4271, and the appropriate transformants were selected by testing β-galactosidase expression and 3-aminoazonole sensitivity according to the manufacturer's instructions. These yeast reporter clones were transformed with DNA from the cDNA library (pACT2) made from human placenta cells (Clontech). We screened ~5×105 clones in
each assay. Yeast cells with His\(^+\) β-gal\(^+\) phenotypes were selected. The cDNA (prey) plasmids from His\(^+\) β-gal\(^+\) yeast colonies were isolated and sequenced.

**Cell lines**

The THP-1 human macrophage-like cell line, Raji human Burkitt lymphoma cell line, HSB-2 human T leukemic cell line and JEG-3 human choriocarcinoma cell line were maintained in DMEM medium containing 10% FBS (IBL, Gunma, Japan), 100 μg/ml streptomycin and 100 U/ml penicillin (22–24).

**Reporter gene assays**

Cells were transfected with the plasmid by the DEAE-dextran method (Stratagene) or the calcium phosphate method (Stratagene) according to the manufacturer’s instructions. THP-1 and Raji cells (10\(^7\) cells/tube) were treated with 10 μg of test plasmid in the presence of 250 μg/ml DEAE-dextran sulfate. JEG-3 cells (1.5×10\(^5\) cells/3.5 cm dish) were transfected by the calcium phosphate method. Two days later, cell lysates were prepared and assayed for chloramphenicol acetyl transferase (CAT), luciferase and β-galactosidase activities. The CAT activity was determined by the method described by Gorman et al. (25). After the incubation period, the products were separated from unacetylated chloramphenicol by thin-layer chromatography. The radioactivity was measured using the Biolmage analyzer BAS2000 (Fuji Film, Tokyo, Japan). The luciferase and β-galactosidase activities were determined with a Luciferase constant light kit (Roche Diagnostics Japan, Tokyo, Japan) and Galacto-Star (Tropix, Bedford, MA) according to the manufacturer’s instructions. We used the pSVβgal plasmid (0.2 μg) for normalizing transfection efficiencies.

**Nucleotide accession**

The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL and GenBank as nucleotide sequence accession no. D86416.

**Results**

**Isolation of the 5’ flanking region of the human FcyRIIB gene and characterization of its promoter region**

The structure of the human FcyRIIB gene was determined using genomic clones isolated from the EMBL3 Japanese genomic library. Figure 1 shows the 5’ flanking sequence of the human FcyRIIB gene. The gene structure of the 5’ boundary of the human FcyRIIB gene in the present study is identical to those reported previously (11,12). By Harr plot analysis, the 5’ flanking sequence of the human FcyRIIB gene showed no apparent homology to that of the human FcyRIA gene reported by McKenzie et al. (16) (data not shown). To determine the transcription start sites, mRNAs from THP-1 and HSB-2 cells that express all three FcR RIIB gene were internally deleted respectively, did not produce a significant level of CAT activity, as shown in Fig. 3(B). Thus, the 5’ boundary for the minimal human FcyRIIB promoter lies between nucleotides –154 and +21.

**Characterization of nuclear factors bound to the 5’ flanking region of the human FcyRIIB gene**

We next determined whether the 5’ flanking region of the FcyRIIB gene has promoter activity. As shown in Fig. 3(A), 4.1-, 2.0- and 2.3-fold increases of the CAT activity of cell extracts from THP-1 cells, Raji cells and JEG-3 cells transfected with pFcRCAT were noted as compared with pSV0OCAT. The pFcRCAT-EN produced 12.0-, 8.9- and 3.9-fold increases of the CAT activity in THP-1, Raji and JEG-3 cells respectively over that produced by pCAT-EN (Fig. 3A). Promoter activity was then mapped by comparing CAT expression driven by a series of 5’ deletion mutants in the FcyRIIB promoter lies between nucleotides –154 and +21.
ZNF140 and ZNF91 repress FcγRIIB transcription

Fig. 2. Mapping of the human FcγRIIB mRNA transcription initiation sites by primer extension analysis. A labeled 23-bp primer complementary to the nucleotides 1–23 of the human FcγRIIB cDNA (structural gene) was hybridized with mRNA from THP-1 human macrophage-like cells (lane 1) or HSB-2 human T leukemic cells (lane 2). Primer was extended by reverse transcriptase, denatured and run on a urea/acylamide gel. The sequence shown at the left was identified using the same primer except for the absence of the 5' phosphate. Arrows indicate primer elongation stop points.

E), we found that two probes [F2 (–126 to –93) and F4 (–64 to –31)] formed specific bands, because cold F2 and F4 probes inhibited formation of specific bands (bands A, B and C) respectively. The other three probes (F1, F3 and F5) did not reveal any specific band (Fig. 4B, D and F). Since the nuclear factor PU.1 recognized a purine-rich sequence (PU box) (26,27) and the F2 region contained a similar nucleotide sequence, we performed supershift analysis using anti-PU.1 or anti-C/EBPβ antibody. As shown in Fig. 4(G), specific bands A, B and C were not supershifted in the presence of anti-PU.1 or anti-C/EBPβ antibody, although anti-PU.1 and anti-C/EBPβ antibodies could supershift the probes containing PU box derived from human FcγRI gene and CCAAT homology region derived from human IL-6 gene respectively (data not shown). Figure 4(H) shows that F2-binding proteins are different from F4-binding proteins, because the F4 nucleotide could not compete with the 32P-labeled F2 probe. Similarly, the F2 nucleotide did not inhibit complex formation with the 32P-labeled F4 probe (data not shown).

To further determine the precise sequences responsible for DNA binding, we next synthesized three overlapping oligonucleotides of the F2 and F4 regions, and performed EMSA (Figs 5 and 6). We found that multiple nuclear factors bound to the F2-3 (–109 to –93) (Fig. 5C) and F4-3 (–47 to –31) (Fig. 6C) oligonucleotides respectively. No specific bands were noted using the F2-1 (Fig. 5A), F2-2 (Fig. 5B), F4-1 (Fig. 6A) or F4-2 (Fig. 6B) probes. We then introduced mutations in the F2-3 region and performed EMSA. As shown in Figs 5(E) and 6(E), the F2-related probes (F2-3-1, F2-3-2 and F2-3-3) and F4-related probes (F4-3-1, F4-3-2 and F4-3-3) lost the ability to bind the 32P-labeled F2-3 and F4-3 probes respectively. Thus, these results indicate that the sequences of GGGAG-GAGC (–105 to –97) and AATTTGTTTGCC (–47 to –36) within the human FcγRIIB gene promoter are responsible for binding of multiple nuclear factors (Figs 5E and 6E).

Cloning of the F2-3 and F4-3 region-binding protein by one-hybrid assay

To identify nuclear proteins that bind to the F2-3 and F4-3 regions of the human FcγRIIB promoter, we used a one-hybrid assay. As bait sequences, we used (GGGAGGAGC)×3 and (AATTTGTTTGCC)×4 for F2-3- and F4-3-binding proteins respectively. We screened ~5×10⁵ clones of a cDNA library prepared from human placenta in each assay. We isolated
Fig. 4. Multiple nuclear factors from various types of cells bind to the −154 bp 5′ flanking region of the human FcγRIIB gene. (A) The DNA sequences of five oligonucleotides used for EMSA. (B–F) Nuclear extracts from THP-1, Raji and JEG-3 cells were mixed with the 32P-labeled probe. An oligonucleotide containing the NF-κB motif was used as an unrelated competitor at a 150 M excess. Bound and unbound probes were separated in native polyacrylamide gel. The arrow indicates the positions of the complex. (G) Nuclear extracts were then prepared, preincubated with antibodies (2 μl/lane) against PU.1 and C/EBPβ, and analyzed by EMSA. The arrow indicates the position of the complex. (H) Nuclear extracts were mixed with the 32P-labeled F2. A 150 M excess of unlabeled oligonucleotide competitors was added. The arrow indicates the position of the complex.
ZNF140 and ZNF91 repress FcγRIIB transcription

Fig. 5. Analysis of the F2 region-specific EMSA complex. (A–C) Nuclear extracts from THP-1, Raji and JEG-3 cells were mixed with the 32P-labeled probe. An oligonucleotide containing the NF-κB motif was used as an unrelated competitor at a 150 M excess. Bound and unbound probes were separated in native polyacrylamide gel. The arrow indicates the positions of the complex. (D) The DNA sequences of four oligonucleotides used for EMSA. (E) Nuclear extracts were mixed with the 32P-labeled F2-3. A 150 M excess of unlabeled oligonucleotide competitors was added. The arrow indicates the position of the complex.

12 and 21 His\(^+\) β-gal\(^+\) clones in the F2-3- and F4-3-binding assays respectively. We then isolated and sequenced cDNA (prey) plasmids, and found that plasmids from two clones (F2-3-binding protein) and three clones (F4-3-binding protein) contained partial sequences that are identical to those of the human zinc-finger protein 140 (ZNF140) (19) and zinc-finger protein 91 (ZNF91) (20) respectively. Other clones were not analyzed in the present study.

To confirm the binding specificity of the two zinc-finger proteins, we transformed yeasts carrying either F2-3-EL/pHiSi-1 and F2-3-EL/pLacZi or F4-3-EL/pHiSi-1 and F4-3-EL/pLacZi with pZNF140/pACT2, pZNF91/pACT2 or pACT2. Colonies were tested for β-galactosidase activity. Figure 7(A) shows the typical results. ZNF140/pACT2 and ZNF91/pACT2 could specifically bind to the F2-3 and F4-3 elements respectively in yeast, so that β-galactosidase activity was detected. Conversely, ZNF140/pACT2 and ZNF91/pACT2 did not interact with the F4-3 and F2-3 elements respectively. Figure 7(B) shows that the full lengths of ZNF140 and ZNF91 consisted of 457 and 1191 amino acid residues respectively. We sequenced the inserts from F2-3- and F4-3-binding clones, and found that the inserts encoded zinc-finger structures of the fragments of ZNF140 and ZNF91 proteins respectively (Fig. 7B, open rectangles). As shown previously (19,20), these transcripts were ubiquitously expressed on various types of cells (data not shown).

ZNF140 and ZNF91 function as repressors in –154 human FcγRIIB promoter-mediated luciferase expression

Having established that two zinc-finger proteins can specifically bind to the F2-3 and F4-3 region respectively, it is of great interest to determine the function of these proteins. We constructed expression plasmids and transfected them into JEG-3 cells with the reporter plasmid (pFcR2-154/pGL3EN). As shown in Fig. 7(C), when either human ZNF140 or ZNF91 was expressed, both proteins inhibited luciferase activity. Furthermore, the two proteins demonstrated an additive suppressive effect when they were simultaneously expressed.
ZNF140 and ZNF91 repress FcγRIIB transcription

Fig. 6. Analysis of the F4 region-specific EMSA complex. (A–C) Nuclear extracts from THP-1, Raji and JEG-3 cells were mixed with the 32P-labeled probe. An oligonucleotide containing the NF-κB motif was used as an unrelated competitor at a 150 M excess. Bound and unbound probes were separated in native polyacrylamide gel. The arrow indicates the positions of the complex. (D) The DNA sequences of four oligonucleotides used for EMSA. (E) Nuclear extracts were mixed with the 32P-labeled F4-3. A 150 M excess of unlabeled oligonucleotide competitors was added. The arrow indicates the position of the complex.

We also obtained the similar results using human 293T and HepG2 cell lines (data not shown).

Discussion

In humans, three FcγRII genes (FcγRIIA, FcγRIIB and FcγRIIC) are differentially regulated in a variety of cells. In the present study, we found that the promoter regions of the human FcγRIIA and FcγRIIB genes are different. First, we found that a Harr plot between the FcγRIIA and FcγRIIB promoter sequences indicated no apparent homology (data not shown). Second, two different transcription start sites were found in the human FcγRIIA promoter. One transcription start site is located at a 5′/3′-UT exon ~1 kb 5′ to the ATG translation initiation codon, while a second start site was mapped near the ATG codon. On the other hand, we found that the single exon continuous with the ATG codon contains at least two transcription start sites in the human FcγRIIB gene, the major one 42 bp 5′ to ATG and a minor one 22 bp 5′ to ATG in THP-1 cells (Figs 1 and 2). We could not detect any transcription start site 5′ to the 42 bp 5′ to the ATG codon by primer extension analysis (data not shown), thus indicating that the human FcγRIIB gene does not contain a discrete 5′-UT region. Our results are similar to those for the mouse FcγRIIA gene (28) and the human FcγRI gene (29–31), both of which have multiple transcription start sites mapped near the ATG codon.

Third, we found that various elements found in the FcγRIIA and FcγRIIB gene promoters are not identical. Thus, all of these findings indicate that the expression profiles of the FcγRIIA and FcγRIIB genes are differentially regulated.

In the present study, we found that the 5′ boundary for the minimal human FcγRIIB promoter lies between nucleotides -154 and +21 in our assay system. This result is similar to those for the human FcγRI (30–34) and mouse FcγRIIA (28) genes, whose promoters have minimal structures (~150 bp upstream of the cap site) with an IFN-γ-responsive region (GRR) and a PU box, and a PU box and myeloid-restricted region (MRR) respectively. Mutation analysis of the F2-3 and F4-3 regions indicated that the sequences of GGGAGGAGC (-105 to -97) and AATTTGTTTGCC (-47 to -36) within the human FcγRIIB promoter participated in the binding by nuclear factors. The sequence of the F2-3 region is similar to that of the PU.1-responsive element, but the PU.1 nuclear factor did not bind to the F2-3 region, since anti-PU.1 antibody did not supershift (Fig. 4G). This result is in contrast to that for the human FcγRI gene promoter, since the PU.1 was shown to bind to the −107 to −74 region of the human FcγRI promoter (32,33). Thus, these results indicate that the expression
and ZNF91 genes were previously isolated by PCR with zinc-region-binding proteins respectively (Fig. 7). These ZNF140 that the human ZNF140 and ZNF91 were the F2-3 and F4-3
regions. Taken collectively, these results indicate that the multiple nuclear factors might contain different nuclear factors for these
region was connected to the luciferase gene (Fig. 7C). We
also found that ZNF91 was also a transcription repressor, although the function of this protein is not yet known. These
results indicate that ZNF140 and ZNF91 function as transcription
repressors when fused to a heterologous DNA-binding domain
from the yeast GAL4 protein (40,41). We extended the previous
findings by indicating that ZNF140 functioned as a transcription
repressor when the human FcγRIIB natural promoter
region. Identiﬁcation of all promoter–region-binding proteins will resolve these issues.

Acknowledgements
We thank T. Iwata and A. Tamori for technical assistance. We also
thank D. Mrozek and T. Matsui for their comments. This work was
partially supported by Japan Health Sciences Foundation.


